Key Drug Launches To Plan For In 2019

03 Sep 2018

• By John Davis

Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.

Rocket — A good launch is important if products are to succeed in the marketplace • Source: Shutterstock

As a supplement to its quarterly Outlook reports, Informa Pharma's Biomedtracker has taken a longer-term look at some key late-stage drugs projected to enter their first markets in 2019. These drugs represent new drug classes, major changes to standards of care, and large market opportunities, say Biomedtracker analysts in a new report, Key Potential Drug Launches In 2019.

Drugs that could be launched during 2019 could include Novartis AG's brolucizumab as a long-acting anti-VEGF therapy for wet...